Victoza (liraglutide; Novo Nordisk) is a member of the glucagon-like peptide-1 (GLP-1) agonist class. GLP-1 agonists are incretin mimetics, mimicking the endogenous gut hormone GLP-1, which stimulates insulin-secreting beta cells in the pancreas. This triggers glucose-dependent insulin secretion, suppressing glucagon secretion, and thereby decreases plasma glucose levels. The major advantage of this class is the associated weight loss, as obesity is a common co-morbidity among type 2 diabetes patients. GLP-1 agonists also delay gastric emptying, thus increasing satiety and suppressing appetite.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Victoza : Diabetes type 2
LIST OF FIGURES 11 Figure 1: Victoza brand franchise for type 2 diabetes – SWOT analysis
12 Figure 2: Datamonitor Healthcare drug assessment of Victoza
13 Figure 3: Datamonitor Healthcare drug assessment scorecard for Victoza
15 Figure 4: Victoza sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES 4 Table 1: Victoza drug profile
6 Table 2: Victoza Phase III data in type 2 diabetes
10 Table 3: Difference in key cardiovascular outcomes between Victoza and placebo
16 Table 4: Victoza sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016–25
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726